In vitro and in vivo data have shown that GLP-1 RAs can reduce the proliferative capacity of a wide range of tumour cell types, including breast, prostate, ovarian, and pancreatic cancers [25,26]. The gene discussed is GCG; the disease is pancreatic neoplasm.